The developmental stage of emerging adulthood covers a wide age span (ages 18-30 years) with potential for differing emotional burdens for those living with type 1 diabetes (T1D) . To further confirm the content validity of the PAID-EA and to investigate differences between younger and older emerging adults, item responses on the newly developed, previously validated PAID-EA survey were examined by age group. Emerging adults (N=287) with T1D completed online measures of diabetes distress, depressive symptomology, and the PAID-EA. The PAID-EA has 25 items and uses a 5 point Likert-type response scale with options ranging from agree to disagree. The sample was split into 2 age groups: younger emerging adults (ages 18-24, N=143) and older emerging adults (ages 25-30, N=122) . Self-reported HbA1c was significantly worse in younger vs. older emerging adults (7.4% vs. 6.8%, p<.001) . Other demographic variables and total scores on measures were similar between age groups. Only 3 items on the PAID-EA differed by age group with younger emerging adults endorsing more diabetes distress: (1) Item 6: “I worry about being able to socialize because of how alcohol affects my blood sugar” (p=.03) , (2) Item 7: “I worry that a new romantic partner will see my diabetes devices or supplies” (p=.04) , (3) Item 25: I feel like I am trying my hardest to take care of diabetes, but it never works” (p=.02) . Experimentation with alcohol and intimacy with new partners may be experienced differently for younger compared with older emerging adults. Intense feelings of burnout and failure may also differ; this finding requires further exploration. Though emerging adulthood spans more than a decade, perceptions of the emotional burden of living with T1D appear consistent for the younger and older age groups, confirming the content validity of the PAID-EA throughout emerging adulthood.


K.Wentzell: None. R.J.Vitale: None. L.M.Laffel: Advisory Panel; Medtronic, Roche Diabetes Care, Consultant; Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompé, Insulet Corporation, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Provention Bio, Inc.


Joslin DRC: P30DK036836 NIH: T32DK007260, T32DK007529

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at